Over a 4 year period, 71 patients from 32 institutions were accrued to this phase III trial with endpoints of response and time to progression. In the IFN arm, there was 1 complete response (CR) and 4 partial responses (PR), with 16 patients demonstrating stable disease, for a response rate of 13.9%. In the IFN + cimetidine arm, there were 2 CR, 8 PR, and 13 patients with stable disease, for a response rate of 28.6%. These response rates were not statistically significantly different (p=0.13). In the IFN arm, the median time to progression was 112 days, which was not significantly different from the 125 days seen in the IFN + cimetidine arm (p=0.87).
The authors conclude that the addition of cimetidine does not improve the activity of IFN in metastatic RCC.
By Christopher G. Wood, M.D.
Kinouchi T, et al.
J Cancer Res Oncol, 2006 Aug;132(8):499-504. Epub 2006 Apr 4
Link Here.
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to:
urotoday
Copyright © 2006 - UroToday
View drug information on Cimetidine.
Our Recommendations:
• Order Nolvadex
• Buy Generic Differin Without Prescription
• Order Antabuse
No hay comentarios:
Publicar un comentario